Why is ORIC down?
Down 45% in 3 months while the S&P 500 fell 10%.
- It filed a prospectus for an at-the-market program for new shares of $200.0M on Feb 23, 2026.
−3Long-term trend
Down 45% in 3 months while the S&P 500 fell 10%.
−3Long-term trend
ORIC's Quality Score fell 1 point on Fri, Nov 20, to -7. Its quiet day ended.
Follow ORIC's trial news. Pro members can get an alert when Oric Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 10.1% a day with no profit behind it |
| Latest filing | 8-K, Nov 16 |
After its last 4 reports it closed +11.9% on average, higher 3 of 4 times.
About 10 quarters
CFO Dominic Piscitelli sold 14,000 shares on Oct 20, under a planned sale. 8 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ORIC is #217 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 217 |
Expected to report Mon Feb 22, after the close (in 93 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.44 a share, from $0.33.
“The increase was primarily due to an increase in external expenses related to the advancement of rinzimetostat, offset by lower enozertinib costs due to timing of manufacturing and clinical costs.”
ORIC's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increases were primarily due to higher professional services costs.”
From its results filing (SEC filing · Nov 16)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 16, 2026 | +2.5% | +6.4% | not yet |
| Aug 3, 2026 | +0.4% | +27.1% | +28.5% |
| May 4, 2026 | -2.3% | -0.6% | -6.7% |
RSI 31.6, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ORIC is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
ORIC scores -7 today, which Breakaway calls Poor. It is #217 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 45% in 3 months while the S&P 500 fell 10%. Cash lasts about 10 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ORIC scores -7 today, which Breakaway calls Poor (below zero). That is #217 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ORIC's -7.
Expected to report Mon Feb 22, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ORIC closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.